# A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

> **NCT05263180** · PHASE1 · UNKNOWN · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** EMB-09

## Key facts

- **NCT ID:** NCT05263180
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-25
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263180, "A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05263180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*